ATOSSA THERAPEUTICS, INC. — Director's Dealing 2016

May 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2016-05-18

Reporting Person: Guse Kyle (CFO, Gen Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-18	Stock Option (right to buy)	$0.263	A	1090000	Acquired	2026-05-18	Common Stock (1090000)	Direct

Footnotes

F1: The options shall vest on a quarterly basis over the next 24 months.